1. Executive summary
2. Global Venous Thromboembolism Market Introduction
2.1. Global Venous Thromboembolism Market – Taxonomy
2.2. Global Venous Thromboembolism Market –Definitions
2.2.1. Drug Type
2.2.2. Disease Type
2.2.3. End User
3. Global Venous Thromboembolism Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Venous Thromboembolism Market Dynamics – Factors Impact Analysis
3.6. Global Venous Thromboembolism Market – Regulations
3.6.1. U.S
3.6.2. Europe
3.6.3. Japan
3.6.4. China
3.7. Global Venous Thromboembolism Market – Product Innovations
4. Global Venous Thromboembolism Market Analysis, 2013 - 2017 and Forecast, 2018 – 2024
4.1. Global Venous Thromboembolism Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Venous Thromboembolism (VTE) Treatment Market Oppurtunity Analysis
5. Global Venous Thromboembolism Market, By Drug Type, 2013 - 2017 and Forecast, 2018 - 2024
5.1. Factor Xa inhibitors
5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.1.3. Market Opportunity Analysis
5.2. Thrombolytic therapy
5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.2.3. Market Opportunity Analysis
5.3. Plasminogen activators
5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.3.3. Market Opportunity Analysis
5.4. Fondaparinux
5.4.1. Global Venous Thromboembolism Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.4.3. Market Opportunity Analysis
5.5. Dabigatran
5.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.5.3. Market Opportunity Analysis
5.6. Warfarin
5.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
5.6.3. Market Opportunity Analysis
6. Global Venous Thromboembolism Market Forecast, By Disease Type, 2013 - 2017 and Forecast, 2018 - 2024
6.1. Deep Vein Thrombosis
6.1.1. Global Venous Thromboembolism Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.1.3. Venous Thromboembolism (VTE) Treatment Market Opportunity Analysis
6.2. Pulmonary Embolism
6.2.1. Venous Thromboembolism (VTE) Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
6.2.3. Venous Thromboembolism (VTE) Treatment Market Opportunity Analysis
7. Global Venous Thromboembolism Market Forecast, By Distribution Channel, 2013 - 2017 and Forecast, 2018 - 2024
7.1. Hospital pharmacies
7.2. Online Pharmacies
7.3. Retail pharmacies
7.3.1. Global Venous Thromboembolism Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
7.3.3. Market Opportunity Analysis
8. Global Venous Thromboembolism Market Forecast, By Region, 2013 - 2017 and Forecast, 2018 - 2024
8.1. North America
8.1.1. Venous Thromboembolism (VTE) Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.1.3. Venous Thromboembolism (VTE) Treatment Market Opportunity Analysis
8.2. Europe
8.2.1. Global Venous Thromboembolism Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.2.3. Venous Thromboembolism (VTE) Treatment Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.3.3. Venous Thromboembolism (VTE) Treatment Market Opportunity Analysis
8.4. Latin America
8.4.1. Global Venous Thromboembolism Drugs Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Venous Thromboembolism (VTE) Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis
8.5.3. Market Opportunity Analysis
8.6. Global Venous Thromboembolism Market - Opportunity Analysis Index, By Type of Vaccine, End User, and Region, 2018 – 2024
9. North America Venous Thromboembolism Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024
9.1. Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Factor Xa inhibitors
9.1.2. Thrombolytic therapy
9.1.3. Plasminogen activators
9.1.4. Fondaparinux
9.1.5. Dabigatran
9.1.6. Warfarin
9.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Deep vein thrombosis
9.2.2. Pulmonary embolism
9.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.3.1. Hospital Pharmacies
9.3.2. Online Pharmacies
9.3.3. Retail Pharmacies
9.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. U.S.
9.4.2. Canada
9.5. North America Venous Thromboembolism Market - Opportunity Analysis Index, By Drug Type, Disease Analysis, Distribution Channel, and Country, 2018 – 2024
9.6. North America Venous Thromboembolism Market Dynamics – Trends
10. Europe Venous Thromboembolism Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024
10.1. Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Factor Xa inhibitors
10.1.2. Thrombolytic therapy
10.1.3. Plasminogen activators
10.1.4. Fondaparinux
10.1.5. Dabigatran
10.1.6. Warfarin
10.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Deep vein thrombosis
10.2.2. Pulmonary embolism
10.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.3.1. Hospital Pharmacies
10.3.2. Online Pharmacies
10.3.3. Retail Pharmacies
10.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Poland
10.4.8. Rest of Europe
10.5. Europe Venous Thromboembolism Market - Opportunity Analysis Index, By Drug Type, Disease Analysis, Distribution Channel, and Country, 2018 – 2024
10.6. Europe Venous Thromboembolism Market Dynamics – Trends
11. Asia-Pacific Venous Thromboembolism Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024
11.1. Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Factor Xa inhibitors
11.1.2. Thrombolytic therapy
11.1.3. Plasminogen activators
11.1.4. Fondaparinux
11.1.5. Dabigatran
11.1.6. Warfarin
11.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Deep vein thrombosis
11.2.2. Pulmonary embolism
11.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.3.1. Hospital Pharmacies
11.3.2. Online Pharmacies
11.3.3. Retail Pharmacies
11.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Venous Thromboembolism Market - Opportunity Analysis Index, By By Drug Type, Disease Analysis, Distribution Channel, and Country, 2018 – 2024
11.6. Europe Venous Thromboembolism Market Dynamics – Trends
12. Latin America Venous Thromboembolism Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024
12.1. Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Factor Xa inhibitors
12.1.2. Thrombolytic therapy
12.1.3. Plasminogen activators
12.1.4. Fondaparinux
12.1.5. Dabigatran
12.1.6. Warfarin
12.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Deep vein thrombosis
12.2.2. Pulmonary embolism
12.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.3.1. Hospital Pharmacies
12.3.2. Online Pharmacies
12.3.3. Retail Pharmacies
12.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Venezuela
12.4.5. Rest of Latin America
12.5. Latin America Venous Thromboembolism Market - Opportunity Analysis Index, By Drug Type, Disease Analysis, Distribution Channel, and Country, 2018 – 2024
12.6. Latin America Venous Thromboembolism Market Dynamics – Trends
13. Middle East and Africa Venous Thromboembolism Market Analysis, 2013 - 2017 and Forecast, 2018 - 2024
13.1. Drug Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Factor Xa inhibitors
13.1.2. Thrombolytic therapy
13.1.3. Plasminogen activators
13.1.4. Fondaparinux
13.1.5. Dabigatran
13.1.6. Warfarin
13.2. Disease Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Deep vein thrombosis
13.2.2. Pulmonary embolism
13.3. Distribution Channel Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.3.1. Hospital Pharmacies
13.3.2. Online Pharmacies
13.3.3. Retail Pharmacies
13.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Venous Thromboembolism Market - Opportunity Analysis Index, By By Drug Type, Disease Analysis, Distribution Channel, and Country, 2018 – 2024
13.6. MEA Venous Thromboembolism Market Dynamics – Trends
14. Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Sanofi (France)
14.2.2. Pfizer Inc. (U.S.)
14.2.3. Daiichi Sankyo Co. Ltd. (Japan)
14.2.4. Bristol Myers Squibb (U.S.)
14.2.5. Johnson & Johnson Services, Inc. (U.S.)
14.2.6. AbbVie Inc. (U.S.)
14.2.7. Merck & Co. (U.S.)
14.2.8. Astellas Pharma Inc. (Japan)
14.2.9. Sawai Pharmaceuticals Co. Ltd. (U.S.)
14.2.10. Abbott Laboratories (U.S.)
14.2.11. Wockhardt Ltd (India)
14.2.12. Bayer AG (Germany)
14.2.13. Dupont Pharm Co. (U.S.)
15. Research Methodology
16. Key Assumptions and Acronyms